Takuya Miyagi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Takuya Miyagi has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Tetsuo Takehara
Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, Amagasaki, Japan
17 shared publications Tomohide Tatsumi
17 shared publications- Hayato Hikita
Department of Gastroenterology and Hepatology The University of Osaka Graduate School of Medicine Suita Osaka Japan
16 shared publications - Minoru Shigekawa
Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan
16 shared publications - Naoki Hiramatsu
Osaka Rosai Hospital Sakai Japan
16 shared publications - Ryotaro Sakamori
Department of Gastroenterology and Hepatology NHO Osaka National Hospital Osaka Japan
16 shared publications
Latest Publications
- 9 November 2026
- Published by Wiley in The Journal of Dermatology
Drug Survival of Systemic Therapies for Psoriasis in the Western Japan Psoriasis Registry: 2024 Update
Drug survival is a useful composite measure reflecting treatment effectiveness, safety, convenience, and patient satisfaction in routine clinical practice. The Western Japan Psoriasis Registry (WJPR) is a prospective multicenter observational registry involving 34 dermatology centers in western Japan that continuously collects real‐world data on systemic therapies for patients with psoriasis. Yanase et al. previously reported drug survival in 1674 treatment episodes initiated between 2010 and 2020 within the WJPR; however, large‐scale real‐world data including recently introduced agents remain limited. We analyzed the drug survival of systemic therapies using data from 2251 patients and 4002 treatment episodes recorded in the WJPR between 2018 and 2024. Drug survival was assessed using the Kaplan–Meier method, and analyses were performed overall and stratified according to body mass index (BMI), psoriatic arthritis (PsA), previous biologic exposure, and sex. Multivariable Cox proportional hazards analyses were also performed for drugs with approved indications for PsA. Drug survival differed among treatments, with risankizumab demonstrating the most favorable persistence throughout the observation period, while guselkumab and ixekizumab also showed favorable drug survival. No significant differences in drug survival were observed according to BMI category. However, drug survival tended to be lower overall in patients with PsA, biologic‐experienced patients, and women. Among patients with PsA, bimekizumab maintained relatively favorable drug survival despite the generally lower treatment persistence observed in this subgroup. Multivariable analyses identified previous biologic exposure as the most consistent predictor of treatment discontinuation, whereas BMI was not independently associated with drug survival in any analyzed drug.
- 9 November 2026
- Published by Wiley in The Journal of Dermatology
Drug Survival of Systemic Therapies for Psoriasis in the Western Japan Psoriasis Registry: 2024 Update
Drug survival is a useful composite measure reflecting treatment effectiveness, safety, convenience, and patient satisfaction in routine clinical practice. The Western Japan Psoriasis Registry (WJPR) is a prospective multicenter observational registry involving 34 dermatology centers in western Japan that continuously collects real‐world data on systemic therapies for patients with psoriasis. Yanase et al. previously reported drug survival in 1674 treatment episodes initiated between 2010 and 2020 within the WJPR; however, large‐scale real‐world data including recently introduced agents remain limited. We analyzed the drug survival of systemic therapies using data from 2251 patients and 4002 treatment episodes recorded in the WJPR between 2018 and 2024. Drug survival was assessed using the Kaplan–Meier method, and analyses were performed overall and stratified according to body mass index (BMI), psoriatic arthritis (PsA), previous biologic exposure, and sex. Multivariable Cox proportional hazards analyses were also performed for drugs with approved indications for PsA. Drug survival differed among treatments, with risankizumab demonstrating the most favorable persistence throughout the observation period, while guselkumab and ixekizumab also showed favorable drug survival. No significant differences in drug survival were observed according to BMI category. However, drug survival tended to be lower overall in patients with PsA, biologic‐experienced patients, and women. Among patients with PsA, bimekizumab maintained relatively favorable drug survival despite the generally lower treatment persistence observed in this subgroup. Multivariable analyses identified previous biologic exposure as the most consistent predictor of treatment discontinuation, whereas BMI was not independently associated with drug survival in any analyzed drug.
- Open Access
- 20 April 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
An Exploratory Study to Identify Factors Associated with Recurrence of Generalized Pustular Psoriasis Flares in Adult Patients in Japan
Generalized pustular psoriasis (GPP) is a rare, systemic inflammatory disease characterized by a heterogeneous and often unpredictable clinical course involving chronic symptoms and recurrent flares. Due to the rarity of GPP, our understanding of factors associated with flare recurrence remains unclear. Using an existing data set of adult patients with GPP in Japan, we performed univariate and multivariate analyses to investigate potential factors related to GPP flare recurrence, including patient demographics, treatment and severity of baseline flare. In total, 150 patients with a baseline flare were included in this analysis; 27.3% (n=41) experienced flare recurrence during the follow-up period (mean duration: 4.16 years). For the overall population, 56.0% of patients were male (n=84), the mean age at baseline was 55.5 years, and the mean body mass index was 24.3 kg/m2. Based on the Cox proportional hazards model, comorbid diabetes mellitus, a fever of ≥38.5°C at baseline flare, experience of flare(s) prior to baseline and certain respiratory infections were associated with a higher risk of flare recurrence, similar to previously published findings. These results could help identify patients at risk of GPP flares; however, clinically applicable prediction of GPP flares requires further research in a wider population.
- 20 April 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Open AccessAn Exploratory Study to Identify Factors Associated with Recurrence of Generalized Pustular Psoriasis Flares in Adult Patients in Japan
Generalized pustular psoriasis (GPP) is a rare, systemic inflammatory disease characterized by a heterogeneous and often unpredictable clinical course involving chronic symptoms and recurrent flares. Due to the rarity of GPP, our understanding of factors associated with flare recurrence remains unclear. Using an existing data set of adult patients with GPP in Japan, we performed univariate and multivariate analyses to investigate potential factors related to GPP flare recurrence, including patient demographics, treatment and severity of baseline flare. In total, 150 patients with a baseline flare were included in this analysis; 27.3% (n=41) experienced flare recurrence during the follow-up period (mean duration: 4.16 years). For the overall population, 56.0% of patients were male (n=84), the mean age at baseline was 55.5 years, and the mean body mass index was 24.3 kg/m2. Based on the Cox proportional hazards model, comorbid diabetes mellitus, a fever of ≥38.5°C at baseline flare, experience of flare(s) prior to baseline and certain respiratory infections were associated with a higher risk of flare recurrence, similar to previously published findings. These results could help identify patients at risk of GPP flares; however, clinically applicable prediction of GPP flares requires further research in a wider population.
- Open Access
- 23 August 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (11) , 1619-1628
An Open‐Label, Multicenter, Phase II Study of Bexarotene in Patients with Adult T‐Cell Leukemia/Lymphoma
A multicenter, open‐label, historically controlled, 2‐arm phase II study was conducted to evaluate the safety, efficacy, and pharmacokinetics of bexarotene in Japanese patients with adult T‐cell lymphoma/leukemia (ATL). The study enrolled patients with indolent ATL and skin lesions and patients with aggressive ATL who had skin relapse after achieving remission following ≥ 1 regimen of systemic chemotherapy. Patients received oral bexarotene at an initial dose of 100 mg/m 2 (15 patients) or 300 mg/m 2 (17 patients) once daily for 24 weeks. The 100 mg/m 2 group included 14 patients with indolent ATL and 1 with aggressive ATL. The 300 mg/m 2 group included 14 patients with indolent ATL and 3 with aggressive ATL. Of 12 patients in the 100 mg/m 2 group, 6 patients achieved complete response (CR) or partial response (PR) as the best overall response (50.0%; 95% confidence interval (CI), 25.4%–74.6%). Of 17 patients in the 300 mg/m 2 group, 12 patients achieved CR or PR (70.6%; 95% CI, 46.9%–86.7%) as estimated with the modified Severity Weighted Assessment Tool (mSWAT). Drug‐related adverse events (AEs) occurred in 15 patients (100%) in the 100 mg/m 2 group and 16 of 17 patients (94.1%) in the 300 mg/m 2 group. The most common AEs were hypothyroidism (75.1%) and hypertriglyceridemia (53.1%). This is the first report to evaluate the safety and efficacy of bexarotene in ATL focused on skin lesions. In both groups, the response rate exceeded the threshold defined for the study. Bexarotene might be effective in improving skin lesions in ATL of any type with good tolerability. Trial Registration: This study was registered with the Japan Registry of Clinical Trials (jRCT2080224172)
- 23 August 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (11) , 1619-1628
Open AccessAn Open‐Label, Multicenter, Phase II Study of Bexarotene in Patients with Adult T‐Cell Leukemia/Lymphoma
A multicenter, open‐label, historically controlled, 2‐arm phase II study was conducted to evaluate the safety, efficacy, and pharmacokinetics of bexarotene in Japanese patients with adult T‐cell lymphoma/leukemia (ATL). The study enrolled patients with indolent ATL and skin lesions and patients with aggressive ATL who had skin relapse after achieving remission following ≥ 1 regimen of systemic chemotherapy. Patients received oral bexarotene at an initial dose of 100 mg/m 2 (15 patients) or 300 mg/m 2 (17 patients) once daily for 24 weeks. The 100 mg/m 2 group included 14 patients with indolent ATL and 1 with aggressive ATL. The 300 mg/m 2 group included 14 patients with indolent ATL and 3 with aggressive ATL. Of 12 patients in the 100 mg/m 2 group, 6 patients achieved complete response (CR) or partial response (PR) as the best overall response (50.0%; 95% confidence interval (CI), 25.4%–74.6%). Of 17 patients in the 300 mg/m 2 group, 12 patients achieved CR or PR (70.6%; 95% CI, 46.9%–86.7%) as estimated with the modified Severity Weighted Assessment Tool (mSWAT). Drug‐related adverse events (AEs) occurred in 15 patients (100%) in the 100 mg/m 2 group and 16 of 17 patients (94.1%) in the 300 mg/m 2 group. The most common AEs were hypothyroidism (75.1%) and hypertriglyceridemia (53.1%). This is the first report to evaluate the safety and efficacy of bexarotene in ATL focused on skin lesions. In both groups, the response rate exceeded the threshold defined for the study. Bexarotene might be effective in improving skin lesions in ATL of any type with good tolerability. Trial Registration: This study was registered with the Japan Registry of Clinical Trials (jRCT2080224172)
- Open Access
- 28 April 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (6) , e430-e480
Wound, pressure ulcer, and burn guidelines (2023)―4: Guidelines for the management of connective tissue disease/vasculitis‐associated skin ulcers, third edition
- 28 April 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (6) , e430-e480
Open AccessWound, pressure ulcer, and burn guidelines (2023)―4: Guidelines for the management of connective tissue disease/vasculitis‐associated skin ulcers, third edition
- 19 July 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (12) , 1634-1640
Real‐world safety and efficacy of biologics in elderly patients with psoriasis: A multicenter observational study
Clinical trials of biologics have frequently excluded elderly patients, resulting in inadequate data on their safety and efficacy. Additionally, evidence of their safety and efficacy remains limited, despite some real‐world studies. To assess the safety and efficacy of biologics in elderly patients with psoriasis, we compared these outcomes in younger patients using data from the West Japan Psoriasis Registry (WJPR). The WJPR consists of approximately 30 facilities in Western Japan, including various healthcare settings. This study enrolled 1395 patients who participated in the 2022 follow‐up survey of the WJPR and were either using or had used biologics during the survey. These included 456 patients in the elderly group (≥65 years) and 939 patients in the younger group (p = 0.0234). Infectious diseases were more prevalent in the elderly group than the younger group; however, no significant difference in the frequency of infectious diseases was found between the two groups (p = 0.0807). Malignant neoplasms occurred significantly more frequently in the elderly group than in the younger group (p = 0.0169). Our results indicate a few concerns about infection when prescribing biologics to elderly patients. Biologics were effective for both elderly and younger patients. We found no significant differences in the proportion of patients with a body surface area score ≤3%, Physician's Global Assessment score 0/1, or Patient's Global Assessment score 0/1, as well as in the mean Dermatology Life Quality Index and the Itch Numerical Rating Scale between the younger and the elderly groups. Overall, our results confirm the appropriateness of using biologics in elderly patients with regard to safety and efficacy.
- 19 July 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (12) , 1634-1640
Real‐world safety and efficacy of biologics in elderly patients with psoriasis: A multicenter observational study
Clinical trials of biologics have frequently excluded elderly patients, resulting in inadequate data on their safety and efficacy. Additionally, evidence of their safety and efficacy remains limited, despite some real‐world studies. To assess the safety and efficacy of biologics in elderly patients with psoriasis, we compared these outcomes in younger patients using data from the West Japan Psoriasis Registry (WJPR). The WJPR consists of approximately 30 facilities in Western Japan, including various healthcare settings. This study enrolled 1395 patients who participated in the 2022 follow‐up survey of the WJPR and were either using or had used biologics during the survey. These included 456 patients in the elderly group (≥65 years) and 939 patients in the younger group (p = 0.0234). Infectious diseases were more prevalent in the elderly group than the younger group; however, no significant difference in the frequency of infectious diseases was found between the two groups (p = 0.0807). Malignant neoplasms occurred significantly more frequently in the elderly group than in the younger group (p = 0.0169). Our results indicate a few concerns about infection when prescribing biologics to elderly patients. Biologics were effective for both elderly and younger patients. We found no significant differences in the proportion of patients with a body surface area score ≤3%, Physician's Global Assessment score 0/1, or Patient's Global Assessment score 0/1, as well as in the mean Dermatology Life Quality Index and the Itch Numerical Rating Scale between the younger and the elderly groups. Overall, our results confirm the appropriateness of using biologics in elderly patients with regard to safety and efficacy.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis
Supplementary Figure 3. Deep sequencing of almost all coding lesions of p53 and beta-catenin.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis
Supplementary Figure 3. Deep sequencing of almost all coding lesions of p53 and beta-catenin.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Sup Materials from Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis
Supplemental Figure legend and Material and Methods
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSup Materials from Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis
Supplemental Figure legend and Material and Methods
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis
Supplementary Figure 3. Deep sequencing of almost all coding lesions of p53 and beta-catenin.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis
Supplementary Figure 3. Deep sequencing of almost all coding lesions of p53 and beta-catenin.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis
Supplementary Figure 2. Bid deficiency suppresses hepatocyte apoptosis and oxidative stress in the livers of Mcl-1 KO mice.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis
Supplementary Figure 2. Bid deficiency suppresses hepatocyte apoptosis and oxidative stress in the livers of Mcl-1 KO mice.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis
Supplementary Table 2. Gene lists called by VIrmed using whole exome sequencing data of tumor lesions and their surrounding non-tumor lesions in Mcl-1 KO mice.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis
Supplementary Table 2. Gene lists called by VIrmed using whole exome sequencing data of tumor lesions and their surrounding non-tumor lesions in Mcl-1 KO mice.